Synopsis: In patients with biliary tract cancer, curative resection is necessary for long-term survival in patients with no more than one lymph node metastasis.
Introduction
The prevalence of biliary tract cancer (BTC) is increasing worldwide, including in Japan, 1, 2 and the cancer ranks as the 7th leading cause of cancer death, following pancreas cancer. 2 The only potential curative treatment for this malignancy is surgical resection, and in regard to the treatment outcomes after surgery, the estimated 2-year survival is 65% and the estimated 5-year survival, 40%. 3, 4 In addition, guidelines still recommend clinical trials of adjuvant therapies, 5, 6 and a prospective clinical trial of adjuvant gemcitabine (GEM) therapy conducted by us showed a 2-year overall survival of approximately 70%. 7 The outcomes were found to be poor; however, we sometimes encounter longterm survivors. Thus, there still seems to be room for further investigation.
To improve the surgical outcomes of patients with any malignancy, the following are considered to be essential; early diagnosis, development of adjuvant therapies, and selection of suitable candidates for surgery. The latter is especially important, particularly in cases of cancer with local invasion or regional lymph node involvement. Accordingly, we focused on long-term survivors in patients with advanced BTC, and explored the characteristics of patients who could benefit from surgery.
In this study, we performed clinicopathological analysis of patients with advanced BTC showing long-term survival using a prospectively collected database, and verified the results using recent patient data which are well-described, especially those with lymph node dissection and metastasis. The analysis revealed that a lower number of metastatic lymph nodes was an important factor for long-term survival, and we verified that BTC patients with no more than one metastatic lymph node would derive benefit from surgery with regional lymphadenectomy.
Materials and methods

Criteria for the classification of biliary tract cancer
In this study, we used the Japanese Society of Biliary Surgery (JSBS) General Rules for classification of biliary cancer, Surgical and Pathological Studies on Cancer of the Biliary Tract (5th edition) 8 to compare the patients' characteristics and assess the pathological residual tumors as reported in our previous studies. 9, 10 We have shown the comparison between the JSBS classification and the TNM classification of malignant tumors of the International Union against Cancer (UICC) in Fig. 1 . Briefly, the fStage III and IV (local invasion or regional lymph node involvement) are equivalent to Stage II and III, fCur A and B (curative resection) are equivalent to R0 resection, and fCur C (non-curative resection) is equivalent to R1 or R2, in the TNM classification of UICC. 11 
Patients and prospectively collected database for this analysis
To perform this analysis, we employed a prospective collected database for biliary tract cancer maintained at our department. In total, 306 patients underwent surgical resection for biliary tract cancer until 2011. There were 170 fStage III and IV patients according to JSBS (extrahepatic bile duct cancer (BDC), 94; gall bladder cancer (GBC), 52; cancer of papilla of Vater (PVC), 24).
Operative procedure and follow-up
After routine examination of the general condition, liver function testing, computed tomography (CT) and/or magnetic resonance imaging, cholangiography, and biliary drainage, if necessary, we performed surgical resection. The procedures performed were determined by the location of the primary tumor; e.g., for hilar and superior BDC, right hemihepatectomy with caudate lobectomy and extrahepatic bile duct resection was performed, while for inferior BDC, pancreatoduodenectomy was performed, with lymphadenectomy in the following regions; hepaticoduodenal ligament, common hepatic artery, aortic lymph node, and superior aspect of the retropancreas for hepatic resection, and around the superior mesenteric artery for pancreatoduodenectomy.
All patients were regularly followed up by abdominal CT and measurement of the serum carcinoembryonic antigen (CEA) every 3 months in the first 2 years and every 6 months thereafter. After the recurrence, we treated patients by chemotherapy, radiation, surgery, or best supportive care, depending on the patients' condition and site and number of recurrences.
Pathological diagnosis
Pathological diagnosis was based on the JSBS classification, as shown in Fig. 1 . For histopathological examination, 6-mm-thick paraffin-embedded sections were prepared for each 5-mm serial section along the axial length of the biliary tract.
Criteria for long-term survivor patients
We set the criterion for long-term survival as patients who survived for more than 5 years after the surgery. As the control group, we employed patients who underwent fCur A/B resection (R0 resection) before 2005 and died within 5 years of the surgery.
Statistical analysis
The overall survival rates were calculated by the KaplaneMeier method and differences between groups were tested by the log-rank test. Differences in the patients' characteristics between groups were analyzed by the Student's t-test or chi-square test. A p-value of <0.05 was considered to indicate statistical significance. The statistical software used was the StatView J-5.0 software (SAS, Cary, NC).
Results
General profile and surgical outcome of patients with advanced BTC
Among the 170 patients with fStage III/IV BTC classified according to the JSBS, 148 (87.1%) showed local invasion to adjacent organs and/or major vessels and 92 (54.1%) showed pathologically proven regional lymph node involvement. The number of patients with fStage III was 45 (26.5%), that with stage IVa was 78 (45.9%), and that with stage IVb was 47 (27.6%). Among these patients, 20 patients (28.6%) underwent resection and reconstruction of the hepatic artery and/or portal vein, and 98 patients underwent fCur A/B resection (R0 resection, 57.6%). In all, 72 patients underwent major hepatectomy (42.3%), 61 underwent pancreatoduodenectomy (35.9%), 7 underwent pancreatoduodenectomy with major hepatectomy (4.1%), and 30 underwent liver S4aþ5 resection and other procedures. After the surgery, 12 patients received adjuvant chemotherapy, including gemcitabine (GEM) or S-1, and 29 patients underwent postoperative irradiation. 10 No patients underwent neoadjuvant chemo (-radiation) therapy.
The median and mean observation periods were 18.6 months and 35.0 months, respectively. The overall 5-year survival rate was 23.9% (20.7% in BDC patients, 24.6% in GBC patients, and 38.2% in PVC patients).
Clinicopathological features of long-term survivors of BTC
The number of long-term survivors was 25 (14.7%) in this study (10 with BDC, 9 with GBC, and 6 with PVC). We described the clinicopathological features of these patients in Table 1A . The number of patients with fStage III was 11, that with stage IVa was 13, and that with stage IVb was one. Six patients underwent major hepatectomy and 13 patients underwent pancreatoduodenectomy. In all, 24 patients underwent fCur A/B surgery. Five patients underwent postoperative irradiation, including one fCur C patient whose pathological hepatic cut end was positive (pHM2, R1). None of the patients underwent Fig. 1 . Growth pattern; alpha; expanding, beta; intermediate, gamma; infiltrating, ly; invasion of lymphatic system, v; invasion of venous system, pn; invasion of nervous system; 0; no invasion, 1; slightly, 2; moderately, 3; markedly. pN1; pathologically positive for lymph node metastasis involvement around primary cancer. pN2; pathologically positive for regional lymph node metastasis involvement. Margin; (À); cancer-free-margin of more than 5 mm in width at surgical cut end. pHM1; cancer e free margin of 5 mm or less in width at the hepatic cut end, pHM2l definite invasion of the hepatic cut end, pEM1; cancer-free-margin of 5 mm or less in width at dissected periductal structures. fCurA; cancer-free-margin of more than 5 mm in width at any surgical cut end, and complete dissection of lymph nodes with pN0 or pN1, fCurB; equivalent to R0 resection, fCurC; equivalent to R1 resection. AMI; acute myocardial infarction.
adjuvant GEM chemotherapy. Tumor recurrence was noted in eight patients at 42.0e110.3 months after the surgery (lymph node metastasis in three and liver metastasis in three patients), and two of these patients underwent surgical resection and the remaining two patients were treated with GEM.
Comparison of characteristics between the long-term survivor group and the control group
We have summarized the comparison in Table 1B . The number of patients in the control group was 52. None of the patients underwent adjuvant GEM chemotherapy. In regard to the clinicopathological features, the long-term survivor group underwent fewer hemihepatectomies, had fewer metastatic lymph nodes, had a lower fStage, and underwent fewer fCur C surgeries. There were no differences in the rates of local invasion and surgical margin positivity, which are the other factors related to fStage and fCur than lymph node involvement.
Clinicopathological features of long-term survivors with lymph node involvement
First, we compared patients with and without lymph node involvement among the long-term survivors (Table 2A ). Only six patients had metastatic lymph node involvement among the 25 long-term survivors. Younger patients who underwent pancreatoduodenectomy with or without partial liver resection showed long-term survival with lymph node involvement, even in the presence of venous invasion. The fStage showed a tendency to be lower in the patients with lymph node involvement. There were no other factors that were different between the patients who were positive and negative for lymph node involvement.
Secondly, we have summarized the characteristics of the primary tumor, operative procedure, and also the location and number of metastatic lymph nodes in Table 2B . Involvement was limited to the regional lymph nodes, and the lymph nodes were located near Bold value signifies p < 0.05. D2þalpha; lymph node dissection around hepaticoduodenal ligament, common hepatic artery, aortic lymph node, and at the superior aspect of the retropancreas for hepatic resection, and around the superior mesenteric artery for pancreatoduodenectomy. a Median (range). the primary tumor, except in cases of gall bladder cancer. The number of lymph nodes involved was one to three in the 6 to 42 dissected regional lymph nodes. In regard to recurrence, one patient, who had one metastatic lymph node, developed metachronous liver metastasis 96.3 months after the surgery, and another patient, who had two metastatic lymph node, developed lymph node recurrence 45.8 months after the surgery (Table 1A , patient #4, #24).
Impact of lymph node involvement on the long-term survival
The above data showed that absence of lymph node is clearly associated with long-term survival, with patients having one to three metastatic lymph nodes showing the possibility of long-term survival. To verify this thesis, we analyzed the overall survival, and also categorized the survival by the number of metastatic lymph nodes. From our database, we employed 147 recent patients from 2000, with clear data available on lymph node involvement. In these patients, 96 patients (65.3%) underwent fCur A and B (R0) surgery. We excluded 11 patients who underwent GEM adjuvant chemotherapy, and we finally analyzed the data of 85 patients (41 BDC, 27 GBC and 17 PVC) with a median observation period of 40.2 months. The average and median number of dissected lymph nodes was 15.2 and 14.5, respectively. We showed the number of patients with each number of metastatic lymph nodes in Table 3A . In all, 74.1% patients were negative for metastatic lymph nodes, and 50% of the remaining patients had only one metastatic lymph node.
Last, the overall survival by the number of metastatic lymph nodes is shown in Table 3B . The three-year overall survival was 65.2%. Statistically significant differences in survival were seen depending on the number of metastatic lymph nodes: between patients with no or one metastatic lymph node vs those with more than two metastatic lymph nodes (p ¼ 0.0304). The survival curve of n ¼ 1 was similar to that of n ¼ 0 (Fig. 2) . The involved/dissected lymph node ratio (LNR) of >0.20 was another prognostic factor (p ¼ 0.0044). Both univariate and multivariate analysis identified the number of metastatic lymph nodes as an important factor predictive of overall survival in these patients (Table 4 ).
Discussion
In this study, we analyzed the factor of long-term survivor as case-controlled study, and we showed the number of metastatic lymph nodes was the key factor for predicting long-term survival in patients with advanced (fStage III or IV according to the JSBS) BTC, and that in patients with less than one metastatic lymph node, survival benefit may be obtained by surgical resection.
After the start of the GEM era, the treatment of BTC has been changing, and we were prompted to focus on the benefits of surgical treatment for the following reasons. Several authors have shown the effectiveness of GEM for unresectable and recurrent BTC. Retrospective analyses have also revealed the survival benefit of GEM therapy, 4, 12, 13 and the ABC-02 trial, a randomized controlled trial, showed that therapy with GEM plus Cisplatin prolonged the patients' survival. 14 Accordingly, in an analysis of the effects of surgical treatment, it is necessary to minimize the influence of GEM, especially in the setting of adjuvant chemotherapy. 7 Because in Japan, GEM therapy has been Abbreviations; see Table 1A . covered by medical insurance from 2006, we analyzed the characteristics of long-term survivors (who survived for over 5 years (surgery before 2006)) among patients who underwent surgery until 2011. It is well-known that the poor-prognostic factors for survival in cases of BTC after surgery are curative resection (fCur A/B or R0 resection), presence of perineural invasion, and presence of lymph node metastasis. 15e23 In regard to curative resection, R1 resection, performed in approximately 30% of BTC patients, 3, 4 seemed to yield a better survival rate than no surgery or R2 surgery. 4, 24 However, even after fCur C (R1), only one patient survived for more than 5 years in our data. One of the keys for long-term survival among BTC patients is still curative resection, and R1 resection was insufficient.
Another important factor was lymph node involvement. Almost all previous reports have shown presence of lymph node metastasis as a poor-prognostic factor. On the other hand, in the case of other gastrointestinal cancers and lung cancer, there have recently been reports of surgical resection yielding survival benefit even in patients with a small number of metastatic lymph nodes. 25, 26 In the case of BTC, Kosuge T et al. showed that patients with metastasis to the local lymph nodes may also benefit from surgery. 27 In our analysis, BTC patients with no more than one metastatic lymph node metastasis could derive benefit from surgery. In addition, some other authors reported the existence of micro-metastasis in BTC. 28, 29 These reports indicate that regional lymph node dissection may provide survival benefit in patients with a small number of metastatic lymph nodes or micro-metastases. On the contrary, we should note that extended lymph node dissection may not provide survival benefit. 18 These indicate the following matter; when the lymph node metastasis is limited, the R0 surgical resection including regional lymph node dissection could also provide the survival in BTC. In contrast, against massive lymph node metastasis, the surgical resection is insufficient and (neo-) adjuvant therapies would be necessary. We also evaluated LNR in this study. As majority of the previous authors in the other gastrointestinal cancers, 25, 26 we employed LNR >0.20. According to univariate analysis, survival benefit could be obtained from surgery in patients with LNR 0.20, however, number of patients with LNR >0.20 was few (n ¼ 3) and we need further verification of the data.
Thus, when the number of metastatic lymph nodes as confirmed by pathological examination was limited, the patients may be expected to derive surgical benefit. The next strategy is detection and adjuvant therapy against lymph node metastasis. Taking into consideration that the three-year survival rate in patients with no or one metastatic lymph node was only 70%, all patients would need adjuvant therapy. However, the relative dose intensity of adjuvant gemcitabine in cases of BTC was only 70%, 7 and there remains the risk of high morbidity and insufficient liver function after the surgery for BTC. This indicates that neoadjuvant therapy would be better because the patients could be treated with a full-dose regimen. On this account, we would need to seek regimens that would yield a tumor control ratio (TCR) in excess of 90% (the TCR obtained with GEM monotherapy was only 50e60% in a pooled analysis 12 ). And, to determine the indications of neo-adjuvant therapy, we need to diagnose pathological lymph node metastasis preoperatively. At present, it is difficult to determine the lymph node status before operation. CT seemed to show a poor detection rate of pathological lymph node involvement. 9, 30, 31 There is the possibility that FDG-PET may be useful for the detection of metastasis 31e35 and this method is expected for selection of the treatment strategy, including neo-adjuvant therapy; however, FDG-PET alone would not always detect lymph node metastasis. Precise prediction method for lymph node metastasis would be necessary for selection of the treatment strategy.
Limitations of this study are the following points; (1) casecontrolled study, (2) few number of patients with massive lymph nodes metastasis (LNR > 0.20), and (3) no long-term survivor of hilar BDC with pathologically positive lymph nodes as Table 2B . For limitation (1), we verified the result using recent 147 patients from our database. In limitation (2), we mentioned this at the previous paragraph. In limitation (3), there remains a possibility of no surgical benefit in hilar BDC with single lymph node metastasis, from our analysis. To overcome these limitations, we need further investigation with larger number of patients.
In conclusion, in BTC patients with no more than one lymph node metastasis, curative resection might yield long-term survival. And, we need to develop a detection method for lymph node metastasis for selection of the treatment strategy.
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